Published in Lancet on December 17, 1977
Cellular and humoral immune reactions in chronic active liver disease. I. Lymphocyte subsets in liver biopsies of patients with untreated idiopathic autoimmune hepatitis, chronic active hepatitis B and primary biliary cirrhosis. Clin Exp Immunol (1982) 2.00
Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut (1979) 1.78
Treatment of hepatic encephalopathy with metronidazole. Gut (1982) 1.61
Detection of monomeric and polymeric IgA containing immune complexes in serum and kidney from patients with alcoholic liver disease. Clin Exp Immunol (1982) 1.35
Detection of circulating immune complexes in alcoholic liver disease. Clin Exp Immunol (1978) 1.21
Alterations of T-cell subsets in primary biliary cirrhosis. Clin Exp Immunol (1982) 1.16
Primary or secondary sicca complex? Investigation in primary biliary cirrhosis by histocompatibility testing. Br Med J (1980) 1.11
Antibodies to a human liver membrane lipoprotein (LSP) in primary biliary cirrhosis. Gut (1980) 1.03
Monomeric (7S) IgM in chronic liver disease. Clin Exp Immunol (1979) 0.95
Role of plasmapheresis in primary biliary cirrhosis. Gut (1985) 0.91
In vitro studies of enhanced IgG synthesis in severe alcoholic liver disease. Clin Exp Immunol (1981) 0.91
Identification of biliary antigens in circulating immune complexes in primary biliary cirrhosis. Clin Exp Immunol (1980) 0.88
Primary biliary cirrhosis and focal glomerulonephritis. Br Med J (Clin Res Ed) (1981) 0.88
Complement activation in chronic liver disease. Clin Exp Immunol (1982) 0.86
Increased C1q binding and arthritis in primary biliary cirrhosis. Gut (1980) 0.83
Expression of adhesion molecules on mature cholangiocytes in canal of Hering and bile ductules in wedge biopsy samples of primary biliary cirrhosis. World J Gastroenterol (2005) 0.82
Localisation of immunoglobulin on the liver cell surface in primary biliary cirrhosis. J Clin Pathol (1981) 0.80
Endothelial cell damage in primary biliary cirrhosis: influence of cholestasis and immunological mechanisms. Clin Exp Immunol (1992) 0.79
A clinical trial of levamisole in primary biliary cirrhosis. Postgrad Med J (1982) 0.77
Circulating immune complexes in Indian childhood cirrhosis. Clin Exp Immunol (1982) 0.75
Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications. Clin Exp Immunol (1966) 8.26
The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med (1973) 6.65
Increase in primary liver cancer in the UK, 1979-94. Lancet (1997) 6.15
Vaccine-induced escape mutant of hepatitis B virus. Lancet (1990) 5.31
Cellular immunity and hepatitis-associated, Australia antigen liver disease. Lancet (1972) 5.17
Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet (1989) 5.16
Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut (1980) 4.09
Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A (1996) 4.02
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut (2002) 4.01
Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med (1995) 3.54
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut (2001) 3.45
Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology (1998) 3.31
Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med (1971) 3.23
Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet (1968) 3.10
Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol (1978) 3.06
The epidemiology of testicular cancer in young adults. Am J Epidemiol (1980) 2.90
The aetiology, presentation and natural history of extra-hepatic portal venous obstruction. Q J Med (1979) 2.84
Spread of acute type-B hepatitis in London. Lancet (1973) 2.82
Measurement of liver-iron concentration in needle-biopsy specimens. Lancet (1971) 2.65
Arterial changes in the lungs in cirrhosis of the liver--lung spider nevi. N Engl J Med (1966) 2.65
Relationship of hepatitis-associated antigen (H.A.A.) to acute and chronic liver injury. Lancet (1971) 2.61
Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology (1994) 2.60
Chronic liver disease and primary liver-cell cancer with hepatitis-associated (Australia) antigen in serum. Lancet (1970) 2.60
Serum ferritin in patients with iron overload and with acute and chronic liver diseases. Gastroenterology (1975) 2.58
Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet (2000) 2.58
The induction of tolerance to a soluble protein antigen by oral administration. Immunology (1974) 2.50
Partial nodular transformation of the liver with portal hypertension. Am J Med (1966) 2.45
Cell-mediated immunity in patients positive for hepatitis-associated antigen. Br Med J (1972) 2.39
Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease. J Pediatr (1993) 2.32
A randomized trial of percutaneous transhepatic cholangiography with the Chiba needle versus endoscopic retrograde cholangiography for bile duct visualization in jaundice. Gastroenterology (1976) 2.25
Diagnosis of Gilbert's syndrome: role of reduced caloric intake test. Br Med J (1973) 2.21
Impaired delayed hypersensitivity in primary biliary cirrhosis. Lancet (1969) 2.19
Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology (1989) 2.15
Role of the liver in controlling the immunogenicity of commensal bacteria in the gut. Lancet (1973) 2.15
The pancreas in primary biliary cirrhosis and primary sclerosing cholangitis. Gastroenterology (1982) 2.11
Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med (1983) 2.10
Complications of diuretic therapy in hepatic cirrhosis. Lancet (1966) 2.09
Immune complexes in ulcerative colitis and Crohn's disease. Clin Exp Immunol (1977) 2.04
Hereditary spherocytosis with secondary haemochromatosis. Lancet (1968) 2.00
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology (1994) 2.00
Immune complexes in acute and chronic liver disease. Clin Exp Immunol (1978) 1.93
The pathology of hepatitis C. Hepatology (1992) 1.92
Evidence for a cerebral effect of the hepatitis C virus. Lancet (2001) 1.90
Incidence and clinical significance of e antigen and antibody in acute and chronic liver disease. Lancet (1975) 1.90
Sex-related differences among 100 patients with alcoholic liver disease. Br Med J (1977) 1.89
Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun (2003) 1.88
Antenatal screening for hepatitis B is medically and economically effective in the prevention of vertical transmission: three years experience in a London hospital. Q J Med (1989) 1.88
Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet (1978) 1.86
Hepatitis-associated antigen in chronic liver disease. Lancet (1969) 1.82
The detection of HBV-DNA in serum by molecular hybridisation: a more sensitive method for the detection of complete HBV particles. J Med Virol (1982) 1.81
Association of primary sclerosing cholangitis with HLA-B8. Gut (1983) 1.79
Hemolytic anemia in Wilson's disease. N Engl J Med (1967) 1.78
Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet (1997) 1.71
Bone disease and calcium absorption in primary biliary cirrhosis with special reference to vitamin-D therapy. Lancet (1968) 1.67
Primary sclerosing cholangitis, the biliary tree, and ulcerative colitis. Gut (1967) 1.67
Short incubation non-A, non-B hepatitis transmitted by factor VIII concentrates in patients with congenital coagulation disorders. Gut (1981) 1.67
The Budd-Chiari syndrome: correlation between hepatic scintigraphy and the clinical, radiological, and pathological findings in nineteen cases of hepatic venous outflow obstruction. Gastroenterology (1975) 1.66
Presentation and course of asymptomatic primary biliary cirrhosis. Gastroenterology (1977) 1.65
Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci U S A (1991) 1.64
Immunological studies in an epidemic of infective, short-incubation hepatitis. Lancet (1972) 1.62
Effects of cyclosporin A on suppressor and inducer T lymphocytes in primary biliary cirrhosis. Lancet (1980) 1.61
Thymus-dependent lymphocyte function in patients with hepatitis-associated antigen. Lancet (1972) 1.60
Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet (1971) 1.60
Natural history of hepatitis-associated antigen-positive chronic liver disease. Lancet (1972) 1.59
Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis. Gut (1986) 1.58
Arsenic and noncirrhotic portal hypertension. Gastroenterology (1974) 1.57
Vitamin A treatment for night blindness in primary biliary cirrhosis. Br Med J (Clin Res Ed) (1984) 1.57
Hepatobiliary fibropolycystic diseases. A clinical and histological review of 51 patients. J Hepatol (1986) 1.55
Immune-complex mediated colitis in rabbits. An experimental model. Gut (1978) 1.54
Percutaneous liver biopsy in patients with large bile duct obstruction. Gastroenterology (1975) 1.53
Chronic pancreatitis: a cause of cholestasis. Gut (1977) 1.51
Mitochondrial and other tissue antibodies in relatives of patients with primary biliary cirrhosis. Clin Exp Immunol (1972) 1.50
Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess (2006) 1.50
Halothane hepatitis. Lancet (1978) 1.50
Is mitochondrial antibody diagnostic of primary biliary cirrhosis? Gut (1981) 1.50
Studies in alcoholic liver disease in Britain. I. Clinical and pathological patterns related to natural history. Gut (1974) 1.50
Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet (1984) 1.49
Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest (1992) 1.48
Idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). A study of 42 families. N Engl J Med (1967) 1.48
Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed) (1987) 1.47
Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology (1997) 1.47
Treatment of ascites by continuous ultrafiltration and reinfusion of protein concentrate. Lancet (1974) 1.46
D-penicillamine treatment improves survival in primary biliary cirrhosis. Lancet (1981) 1.45
Diagnosis of primary cancer of the liver. Br Med J (1971) 1.45
Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology (1985) 1.45
Clinical diagnosis of the Budd-Chiari syndrome. A report of six cases. Am J Med (1967) 1.45
Immunoglobulin-containing cells in the liver. Clin Exp Immunol (1969) 1.44
Detection of serum HBV-DNA by molecular hybridisation. Correlation with HBeAg/anti-HBe status, racial origin, liver histology and hepatocellular carcinoma. J Hepatol (1985) 1.43
Peripheral blood lymphocyte populations in chronic liver disease. Clin Exp Immunol (1976) 1.43
Histological demonstration of copper and copper-associated protein in chronic liver diseases. J Clin Pathol (1978) 1.42
Pseudomembranous colitis following clarithromycin therapy. Eur J Gastroenterol Hepatol (1995) 1.40
Significance of delta agent infection in chronic hepatitis B virus infection: a study in British carriers. Gut (1983) 1.40